Johnson & Johnson

Oncology

In conversation with Johnson & Johnson experts at ESMO 2025, discussing T-cell-redirecting bispecific antibodies and the future of immunotherapy.

News

Thousands of people in the UK have joined a lawsuit against Johnson & Johnson, claiming that it knowingly sold talc products that caused cancer.

News

Johnson & Johnson has said it wants to spin off its orthopaedics division as part of an effort to redirect its business towards higher-growth areas.

News

Johnson & Johnson has suffered a setback in its long-running legal defence against claims its talc products cause cancer.

News

Johnson & Johnson has brought its bladder cancer drug TAR-200 to the US market, a year after its prospects were dented by a negative phase 3 readout.

News

Johnson & Johnson has filled in some of the detail in its $55 billion investment in US facilities announced earlier this year.